Penny Stock Kezar Life Sciences Rejects Acquisition Deal From Concentra Biosciences At $1.10/Share, Shelves Mid-Stage Lupus Nephritis Study – Benzinga

Biotech company Kezar Life Sciences has declined an acquisition offer from Concentra Biosciences at $1.10 per share. In addition to rejecting the deal, Kezar has also decided to put a halt to their mid-stage study on Lupus Nephritis.